Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03063762 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
NCT03063762 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 69 participants.
The verdict
NCT03063762, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
Study Summary
This is an open-label, multi-center, randomized, Phase 1b, adaptive, clinical study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary therapeutic activity of RO6874281 in combination with atezolizumab with/without bevacizumab in participants with unresectable advanced and/or metastatic RCC. The study will consist of a dose-escalation part and an extension part.
Interventions
- DRUG Bevacizumab
- DRUG Atezolizumab
- DRUG RO6874281
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2017-03-20 |
| Est. Completion | 2021-06-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03063762
The ClinicalTrials.gov registry entry for NCT03063762 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT03063762 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03063762 about?
NCT03063762 is a clinical study titled "Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)". This is an open-label, multi-center, randomized, Phase 1b, adaptive, clinical study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary therapeutic activity of RO6874281 in combination with atezolizumab with/without bevacizumab in participants with unresectable ad...
What is the current status of trial NCT03063762?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2017-03-20. Estimated completion is 2021-06-14.
What interventions are being tested in trial NCT03063762?
The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG), RO6874281 (DRUG).
Who is sponsoring clinical trial NCT03063762?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.